# A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma

> **NCT02608125** · PHASE1 · TERMINATED · sponsor: **Principia Biopharma, a Sanofi Company** · enrollment: 45 (actual)

## Conditions studied

- Solid Tumors
- Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter

## Interventions

- **DRUG:** PRN1371

## Key facts

- **NCT ID:** NCT02608125
- **Lead sponsor:** Principia Biopharma, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10-28
- **Primary completion:** 2020-06-23
- **Final completion:** 2020-06-23
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** focus portfolio on immune-mediated diseases
- **Last updated:** 2020-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02608125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02608125, "A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02608125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*